BerGenBio ASA
METHOD
Last updated:
Abstract:
The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
Status:
Application
Type:
Utility
Filling date:
10 May 2019
Issue date:
5 Mar 2020